Research & Development: Page 37
-
PharmaVoice Team/PharmaVoice
Principal Investigator Turnover
The principal investigator (PI) landscape is in flux. According a 2015 survey from the Tufts Center for the Study of Drug Development, persistently high turnover rates among PIs create instability and present an additional challenge for sponsors and CROs. While the number of investigators globall...
By Denise Myshko • Sept. 1, 2016 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
New Company Launches to Address Preclinical Research Trending now: Vium aims to bridge the technology gap in preclinical research to accelerate drug development. Vium has officially launched, offering Digital Vivarium and Vium Cloud, which bridge a technology gap in preclinical in vivo drug rese...
By PharmaVoice Team • Aug. 1, 2016 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Who's On The List by Section
This article contains the list of 100 honorees. If you want to read the article featuring a particular person, please view the Section in which he/she is featured. Commanders & Chiefs Julie Adrian Chandler Chicco Agency, inVentiv Health Mary Anderson Ogilvy CommonHealth Medical Educatio...
By PharmaVoice Team • Aug. 1, 2016 -
PharmaVoice Team/PharmaVoice
Born Leaders A Global Perspective
This year, the homelands of the PharmaVOICE 100 account for almost 20 different countries or territories — from Russia to the West Indies, from Scotland to New Zealand, and from the United States to Australia and various points in between. Six of our honorees — Ken Keller, Stu Libby, Jennifer Mat...
By PharmaVoice Team • Aug. 1, 2016 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Scurvy + Science In May 1747, the HMS Salisbury of Britain’s Royal Navy fleet was patrolling the English Channel at a time when scurvy is thought to have killed more British seamen than French and Spanish arms. According to the Association of Clinical Research Professionals (ACRP), aboard this sh...
By Taren Grom • June 1, 2016 -
PharmaVoice Team/PharmaVoice
UpFront
Industry at Large Sanofi Genzyme Donates Corporate Archives To Harvard Business School Sanofi Genzyme is donating materials to create an extensive archival collection, spanning the more than three decades since the company’s founding in 1981, to the Historical Collections of Harvard Business Scho...
By PharmaVoice Team • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
A “Universal" Flu Vaccine in the Works Tim Alefantis, Ph.D., Sanofi Pasteur’s R&D lead on the second-generation vaccine program, and Sam Lee, Ph.D., project strategy for Sanofi Pasteur’s pandemic and new influenza vaccines, talk about the company’s work to develop a broadly effective influen...
By Tim Alefantis • June 1, 2016 -
PharmaVoice Team/PharmaVoice
2016 DIA Preview
This year’s annual meeting of the Drug Information Association is expected to draw more than 7,000 attendees for the largest global interdisciplinary gathering of life-sciences professionals. DIA 2016 is packed with more than 175 educational offerings over 22 tracks on today’s hottest topics, and...
By PharmaVoice Team • June 1, 2016 -
PharmaVoice Team/PharmaVoice
CNS Research Challenges
Neurological disorders consist of more than 600 conditions, impacting an estimated 50 million Americans every year. Although some are well known, many are rare disorders that affect a small number of patients who currently have access to few, if any, effective treatments. Research in the CNS area...
By Denise Myshko • June 1, 2016 -
PharmaVoice Team/PharmaVoice
China: An Emerging Pharmaceutical Super Power
Over the past 25 years, China has been on an extraordinary economic trajectory. Economic and political reforms that were implemented in the latter part of the last century have transformed the country. “The result is the emergence of a new economic and political super power with global GDP perfor...
By Kim Ribbink • June 1, 2016 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Clinical Trial Solutions: Serving the Clinical Trial Ecosystem
With drug development costs topping $2 billion, R&D spending at an all time high, and as the global market for clinical trials continues to grow and diversify, there is increasing pressure on the industry to bring drugs, biologics, and devices to market with increased speed and greater effici...
By Taren Grom • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Inside the Central Laboratory Model For Clinical Trials Diagnostic Testing
Central laboratories — charged with providing harmonized clinical diagnostic testing and a consolidated database for clinical trial sponsors — continue to evolve against the backdrop of an increasingly complex clinical trial environment. Today the industry balances the demands of complicated labo...
By Mark Engelhart • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Are You Ready for Risk-Based Monitoring? Conditions for RBM Readiness
Choosing your first risk-based monitoring (RBM) program is a big decision. As RBM continues to gain traction in many clinical programs across our industry, it is important to know how to evaluate when RBM is the best choice for your development program. Service providers have been confronted by v...
By Cheryle Evans • June 1, 2016 -
PharmaVoice Team/PharmaVoice
More Than Child's Play: Uncovering the Role of Video Games in Patient Education
Over the past few decades, advances in technology and creative talent from programmers, artists, and writers have spawned a new generation of video games and those who play them, contributing to a $22.4 billion market. Many people assume video games are for entertainment only, but that assumption...
By Allison R. Musante • June 1, 2016 -
PharmaVoice Team/PharmaVoice
How Bring Your Own Device and Other Innovations Are Improving Patient Engagement
Improving how patients participate in clinical trials is an essential challenge for the industry. The past few years have seen an encouraging shift of attention to the various ways we can improve patient engagement in research programs. In the past, patient engagement focused on how we recruit su...
By Adam Butler • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Patient-Centricity Key to Rare Disease Trial Success
Patient-centricity has become a buzzword in the clinical development world. But for rare disease trials, “putting patients first" isn’t just an ideal, it’s an essential element to the success of such studies. The challenges of recruiting and retaining sufficient patient numbers to power a study t...
By Scott Gray • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Shared Investigator Platform Making Life Easier For Clinical Investigators
Life sciences companies are under continual pressure to reduce clinical trial costs and the time it takes to bring a new therapy to market. Clinical trial challenges include subject retention, medical adherence, and managing the huge volume of administrative documents and tasks required of invest...
By Bhaskar Sambasivan • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Clinical Performance Management
Today, global biopharma and medical device companies lament their inability to effectively harness the wealth of data they generate to help guide their thinking and inform decisions. The result is that organizations require valuable resources to spend enormous amounts of time preparing reports t...
By Larry Florin • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Thoughtful Technology to Reduce Burden For Clinical Trial Sites and Patients
The concept of patient-centricity in research is about offering patients a better clinical trial experience. As such, there are a variety of ways to enhance the engagement of the patient. These include empowering other key stakeholders — sponsors, CROs, and sites — with better tools to improve th...
By Kevin T. Williams • June 1, 2016 -
PharmaVoice Team/PharmaVoice
An Industry Call to Action: A Convergence Model Driven By Real World Intelligence
As payers escalate measures to contain costs, providers adjust to new models such as the Affordable Care Act, and patients assume more financial responsibilities for their care, manufacturers are being forced to generate more complex and comprehensive bodies of real world evidence (RWE) about dru...
By Ramita Tandon • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Industry Trends for Life-Science Talent
What workforce trends can the life-sciences industry expect to see through the end of 2016? Developments that were set in motion in the past two years will continue to disrupt the market, broadening the life-sciences workforce spectrum, and change how top talent wants to be engaged. Workforce En...
By Kevin D. Duffy • June 1, 2016 -
PharmaVoice Team/PharmaVoice
How Uber's Tech Model Is Driving Improvements in Clinical Trial Payments
In Tom Goodwin’s oft-quoted article in TechCrunch last year, he says: “Uber, the world’s largest taxi company, owns no vehicles. Facebook, the world’s most popular media owner, creates no content. Alibaba, the most valuable retailer, has no inventory. And Airbnb, the world’s largest accommodation...
By April Mulroney • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Biomarkers Supporting Clinical Trials: A Quality Driven & Integrated Approach to Advancing Drug Development
The pharmaceutical industry faces major challenges; patent expiry, generic competition, weak pipelines, spiralling R&D costs, high attrition rates, and falling drug approval rates. In response, the drug development landscape is set for major changes in the coming five to 10 years. Most pharma...
By Paul Travis • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Assessing SaaS Vendors in Clinical Research: Best Practices to Ensure Compliance
As the adoption of digital technology such as cloud-based data capture and management into clinical research has increased, the scope and complexity of conducting – and, therefore, preparing for – regulatory audits have become more complex. This trend, coupled with the expansion of trials across ...
By Anu Virkar • June 1, 2016 -
PharmaVoice Team/PharmaVoice
Cancer Immunotherapy and Other Advanced Therapies: Opportunity and Challenges Combine to Bring Tomorrow's Treatments to Patients
The immunotherapy field holds great promise. Many of these therapies represent a “breakthrough“ in cancer treatment, as well as other diseases and disorders, and may revolutionize the way we treat various illnesses. As an example, immunotherapy treatments for oncology can be delivered using a va...
By Etienne Drouet • June 1, 2016
Previous
